02.17.21 Why Did Veeva Become A Public Benefit Corporation?
With the spread of SARS-CoV-2 (COVID-19) intensifying, scientists, together with pharmaceutical companies, are reinventing the approach of how to bring life-saving drugs to market. Attend this webinar to learn more about bringing life-saving drugs to market faster without impacting product quality, safety, or efficacy and the impacts and comparisons of classic platforms vs. new-generation platforms. And more!
By Ed Miseta, chief editor, Clinical Leader
On February 1, 2021, Veeva Systems officially became a Public Benefit Corporation (PBC). With this move, it becomes the first technology company supporting life sciences to transition to a PBC and it is also the first publicly traded corporation in any industry to make that move. How will the designation benefit the company?
01.06.21 X4 Pharma Adjusts Clinical Trials For A COVID-19 World
The goal of this report is to help readers stay on top of trends such as the use of challenge trials, diagnostic development, and how companies are responding to the COVID-19 pandemic. Over 130 Phase 1 decision-makers were surveyed to share insights into where the Phase 1 market is now and what changes they expect over the next four years. Click here to learn more.
Featured Editorial
By Ed Miseta, chief editor, Clinical Leader
With the COVID-19 pandemic afflicting patients around the world, those with a compromised immune system are at even greater risk. X4 Pharma is currently conducting a global Phase 3 trial that was already underway when the pandemic hit and concerns patients who are immunocompromised.